More patients with oligoarticular psoriatic arthritis (PsA) saw symptoms largely disappear when apremilast (Otezla) was ...

USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...

Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...

Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration ...

Improvements in 2 patient-reported outcome measures were observed among patients with psoriasis treated with deucravacitinib vs placebo or apremilast.

Apremilast (Otezla) is a new kind of drug that's FDA-approved for psoriatic arthritis and plaque psoriasis. It's a small-molecule phosphodiesterase inhibitor. Apremilast specifically stops the ...

Otezla (apremilast) is a brand-name tablet prescribed for psoriatic arthritis, plaque psoriasis, and mouth ulcers due to Behçet’s disease. As with other drugs, Otezla can cause side effects ...

Otezla (apremilast) is a prescription drug that’s used to treat psoriatic arthritis, plaque psoriasis, and certain types of ulcers. This drug can interact with other medications, such as rifampin.

THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food ...